SEC Company Response from Akari Therapeutics Plc (AKTX) (CIK 0001541157) (AKTX) — Jan 31, 2013
Akari Therapeutics Plc (AKTX) (CIK 0001541157)
Date: Jan. 31, 2013 · CIK: 0001541157 · Accession: 0001144204-13-004921
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-185247
Letter
VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Attention: Rose Zukin, Esq. Registration Statement on Form F-1 Filed December 3, 2012, as amended on December 27, 2012 and January 22, 2013 File No. 333-185247
Dear Ms. Zukin:
With respect to the above-referenced Registration Statement on Form F-1 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Morria Biopharmaceuticals PLC (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the Registration Statement to Friday, February 1, 2013 at 11:00 a.m., or as soon as practicable thereafter.
In connection with the foregoing request, the Company acknowledges the following:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The cooperation of the staff in meeting the timetable described above is very much appreciated. Please call Jeffrey P. Schultz of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (212) 692-6732 with any comments or questions regarding the Registration Statement.
Very truly yours,
/s/ Dov Elefant
Show Raw Text
CORRESP
1
filename1.htm
Morria Biopharmaceuticals Plc
London Office
53 Davies street
Mayfair
London W1K 5JH
Tel: +44 (0)207 152 6341
Fax: +44 (0) 207 152 6342
Email: info@morria.com
Registered Address
Thames House
Portsmouth Road
Esher
Surrey
KT10 9AD
January 31, 2013
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Rose Zukin, Esq.
Re:
Morria Biopharmaceuticals PLC
Registration Statement on Form F-1
Filed December 3, 2012,
as amended on December 27, 2012 and January 22, 2013
File No. 333-185247
Dear Ms. Zukin:
With respect to the
above-referenced Registration Statement on Form F-1 (the “Registration Statement”), and pursuant to Rule 461 of Regulation
C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of Morria Biopharmaceuticals
PLC (the “Company”), that the Securities and Exchange Commission (the “Commission”) accelerate the effective
date of the Registration Statement to Friday, February 1, 2013 at 11:00 a.m., or as soon as practicable thereafter.
In connection with
the foregoing request, the Company acknowledges the following:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing
effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The cooperation of
the staff in meeting the timetable described above is very much appreciated. Please call Jeffrey P. Schultz of Mintz, Levin, Cohn,
Ferris, Glovsky and Popeo, P.C., counsel to the Company, at (212) 692-6732 with any comments or questions regarding the Registration
Statement.
Very truly yours,
/s/ Dov Elefant
Dov Elefant
Chief Financial Officer
Cc:
Mark Cohen, Executive Chairman
Jeffrey Schultz, Esq. 7994721v.1